Philip Nelson is a Managing Director at Secretariat. Before joining the firm, Dr. Nelson was Assistant Director for Competition Analysis at the FTC. He taught economics at Yale University and antitrust law at Fordham Law School. While at the FTC, he served on the FTC’s Merger Screening and Evaluation Committees. Dr. Nelson has written numerous articles and two books, CORPORATIONS IN CRISIS: BEHAVIORAL OBSERVATIONS FOR BANKRUPTCY POLICY and U.S. INTERNATIONAL COMPETITIVENESS. He also edited the ABA Antitrust Section’s MARKET POWER HANDBOOK: COMPETITION LAW AND ECONOMIC FOUNDATIONS. 

Dr. Nelson is an expert in antitrust matters involving mergers, price fixing, unfair competition, vertical restraints, and the Robinson-Patman Act. He has also served as an economic expert in matters involving, intellectual property disputes (including both patent disputes and copyright disputes), damage estimation, class certification, contract disputes, transfer pricing, royalty disputes, FERC regulation of pipelines, Lanham Act, international trade disputes (including both dumping and Sect. 232 cases), and compensation under the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA).

He has testified at trial before judges, juries, and arbitration panels. Among the industries he has analyzed are: pharmaceuticals, oil, natural gas, minerals, refining pipeline, gasoline retailing, oil field equipment, defense, pesticides, grocery products, wholesaling, publishing, vehicle manufacture, automotive parts, toys, electrical equipment, machine tools, plastics, chemicals, metals, household products, security exchanges, telecommunications, electrical utilities, insurance, cameras, computer hardware and software, integrated circuits, cable television, newspapers, fast-food, and health-care technologies and services.

Dr. Nelson is currently on the ABA Antitrust Section’s Long Range Planning Committee, but earlier served on the Section’s Council and as a chair and/or vice chair of the Section’s Economics, Intellectual Property, and Health Care and Pharmaceuticals Committees.